These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 8148235)
41. An eye's view of T regulatory cells. Stein-Streilein J; Taylor AW J Leukoc Biol; 2007 Mar; 81(3):593-8. PubMed ID: 17194735 [TBL] [Abstract][Full Text] [Related]
42. Fas ligand as a tool for immunosuppression and generation of immune tolerance. Bohana-Kashtan O; Civin CI Stem Cells; 2004; 22(6):908-24. PubMed ID: 15536183 [TBL] [Abstract][Full Text] [Related]
43. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Dana MR; Dai R; Zhu S; Yamada J; Streilein JW Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):70-7. PubMed ID: 9430547 [TBL] [Abstract][Full Text] [Related]
44. Immunological privilege in the eye: a review. Tompsett E; Abi-Hanna D; Wakefield D Curr Eye Res; 1990 Dec; 9(12):1141-5. PubMed ID: 2091893 [TBL] [Abstract][Full Text] [Related]
45. Experimental acute hematogenous osteomyelitis in mice. II. Influence of Staphylococcus aureus infection on T-cell immunity. Yoon KS; Fitzgerald RH; Sud S; Song Z; Wooley PH J Orthop Res; 1999 May; 17(3):382-91. PubMed ID: 10376727 [TBL] [Abstract][Full Text] [Related]
46. Tolerance and immunity in the intestinal immune system. Nagler-Anderson C Crit Rev Immunol; 2000; 20(2):103-20. PubMed ID: 10872893 [TBL] [Abstract][Full Text] [Related]
47. Modulation of regulatory T cell immunity by the neuropeptide alpha-melanocyte stimulating hormone. Taylor AW Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):143-9. PubMed ID: 12887097 [TBL] [Abstract][Full Text] [Related]
48. Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Hori J; Vega JL; Masli S Ocul Immunol Inflamm; 2010 Oct; 18(5):325-33. PubMed ID: 20849282 [TBL] [Abstract][Full Text] [Related]
49. Mechanisms of immune privilege in the posterior eye. Stein-Streilein J Int Rev Immunol; 2013 Feb; 32(1):42-56. PubMed ID: 23360157 [TBL] [Abstract][Full Text] [Related]
52. The assessment of epididymal lymphatics within the concept of immunologically privileged sites. Kazeem AA Lymphology; 1983 Sep; 16(3):168-71. PubMed ID: 6605461 [TBL] [Abstract][Full Text] [Related]
54. Studies on the ontogeny of the mouse immune system. I. Cell-bound immunity. USNRDL-TR-67-152. Tyan ML Res Dev Tech Rep; 1967 Dec; ():1-14. PubMed ID: 5300772 [No Abstract] [Full Text] [Related]
55. Immune privilege in the eye: an evolutionary adaptation. Jiang LQ; Streilein JW; McKinney C Dev Comp Immunol; 1994; 18(5):421-31. PubMed ID: 7535254 [TBL] [Abstract][Full Text] [Related]
57. The uterine cervix--a new member of the family of immunologically exceptional sites? Höglund P; Kärre K; Klein G Cancer Immun; 2003 Jul; 3():6. PubMed ID: 12844288 [TBL] [Abstract][Full Text] [Related]
58. Ocular Immune Privilege and Transplantation. Taylor AW Front Immunol; 2016; 7():37. PubMed ID: 26904026 [TBL] [Abstract][Full Text] [Related]
59. [Anatomy and immunology of the eye]. Pleyer U; Pohlmann D Z Rheumatol; 2017 Oct; 76(8):656-663. PubMed ID: 28710528 [TBL] [Abstract][Full Text] [Related]
60. Cell death and immune privilege. Ferguson TA; Green DR; Griffith TS Int Rev Immunol; 2002; 21(2-3):153-72. PubMed ID: 12424841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]